MBCI
MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure Inc. in January 2008 to reflect its new business plan. MabCure Inc. was founded in 2006 and is based in White Plains, New York.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2011 Q4 | -0.18 | $500,000 | $145,250 |
| 2011 Q3 | -0.00 | $0 | -$82,188 |
| 2011 Q2 | -0.01 | $0 | $6,922 |
| 2011 Q1 | -0.01 | $0 | -$131,371 |
| 2010 Q4 | -0.01 | $0 | -$98,652 |
| 2010 Q3 | -0.00 | $0 | -$168,565 |
| 2010 Q2 | -0.00 | $0 | -$197,375 |
| 2010 Q1 | -0.00 | $0 | -$262,073 |